HC Wainwright & Co. Reiterates Buy on Annovis Bio, Maintains $30 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on Annovis Bio (NYSE:ANVS) with a maintained price target of $30.

April 30, 2024 | 10:25 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Annovis Bio's stock rating was reiterated as Buy by HC Wainwright & Co. with a price target of $30.
The reiteration of a Buy rating and a maintained price target of $30 by a reputable analyst firm like HC Wainwright & Co. is likely to instill confidence among investors and could positively influence Annovis Bio's stock price in the short term. Analyst ratings, especially from well-regarded firms, often have a significant impact on how stocks are perceived in the market, potentially leading to price movements.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100